Evans D M, Jones D M, Pitt G R, Ashworth D, De Clerck F, Verheyen F, Szelke M
Ferring Research Institute, University of Southampton Research Centre, UK.
Immunopharmacology. 1996 May;32(1-3):117-8. doi: 10.1016/0162-3109(95)00069-0.
We have developed a series of novel, potent low molecular weight (4-600 Da) inhibitors of TK which were stable to cleavage by the enzyme and showed a high degree of selectivity for TK over several other serine proteases. Compound 7 (CH-2856) was found to reduce eosinophilia in a model of allergic inflammation. The effects observed in vivo provide further evidence for the involvement of TK and kinins in the pathophysiology of allergic diseases such as asthma.
